Latest 10-K annual reports

Arrow Financial Corporation filed an amendment to its 2025 Annual Report on Form 10-K to include its previously omitted Clawback Policy.

SBC Medical Group Holdings Incorporated reported a 9.33% increase in net income for 2025, alongside strategic acquisitions and ongoing international expansion, despite a 15.48% decrease in total revenues.

HG Holdings, Inc. reported a significant increase in total revenues for 2025, driven by growth in management fees and title insurance premiums, leading to a return to net profitability despite an investment impairment.

Werewolf Therapeutics, Inc. announced a significant restructuring, including a 64% workforce reduction, and is exploring strategic alternatives to address substantial doubt about its ability to continue as a going concern.

Dolphin Entertainment significantly reduced its net loss in 2025 while growing revenue, despite increasing debt and ongoing internal control challenges.

Instil Bio, a biotechnology company, has discontinued its lead product candidate AXN-2510 and is now actively seeking to acquire new therapeutic candidates, facing ongoing significant losses and a going concern indicator.

Clear Channel Outdoor Holdings, Inc. filed an amendment to its 2025 Annual Report to include detailed information on executive compensation, corporate governance, and director independence.

American Bitcoin Corp. reports significant Bitcoin reserve growth and improved mining efficiency for fiscal year 2025, following strategic mergers and capital raises.

Luminar Technologies, a LiDAR technology company, has filed for Chapter 11 bankruptcy, sold substantially all of its assets, and is proceeding with a plan of liquidation.

Wen Acquisition Corp.'s 2025 10-K details its ongoing search for a fintech business combination, highlighting strong trust account growth but also significant operational risks and a going concern warning.

Globa Terra Acquisition Corporation, a blank check company, filed its annual report detailing its financial position, search strategy for a business combination in agribusiness and water sectors, and the risks associated with its SPAC structure.

Churchill Capital Corp XI, a blank check company, filed its annual 10-K report, outlining its initial public offering, search for a business combination, and financial position as of December 31, 2025.

Proem Acquisition Corp. I, a blank check company, completed its Initial Public Offering and private placement in February 2026, raising $130 million for its trust account, and outlined its strategy to acquire a high-growth technology-driven enterprise.

Nu Ride Inc. reports a significantly reduced net loss for 2025, focusing on litigation against Foxconn and new billboard loan investments post-bankruptcy.

Southland Holdings, Inc. reported a significant net loss of $308.4 million for 2025, driven by an adverse legal ruling and declining revenue and backlog.

SpyGlass Pharma, Inc. reports significant progress in its BIM-IOL System for glaucoma, initiating two Phase 3 clinical trials and completing a successful IPO in early 2026, despite ongoing financial losses.

GP-Act III Acquisition Corp., a blank check company, filed its 2025 Annual Report on Form 10-K, detailing its financial position, ongoing search for a business combination, and associated risks.

Seafarer Exploration Corp. reports significant operating losses, a substantial working capital deficit, and auditor doubts about its ability to continue as a going concern for the year ended December 31, 2025.

DBV Technologies reports positive Phase 3 VITESSE results for its Viaskin Peanut patch in children aged 4-7, secures significant financing, and outlines accelerated regulatory pathways for both toddler and child populations in the U.S.

Abercrombie & Fitch Co. reported a 6% increase in net sales for Fiscal 2025, reaching $5.27 billion, but saw a decline in operating income and net income compared to the prior year, alongside a strategic review of its APAC business.

Dermata Therapeutics shifts focus from prescription drugs to direct-to-consumer and B2B skincare products, reporting continued losses and a going concern warning.

Oramed Pharmaceuticals Inc. reports a significant net income swing in 2025, driven by strategic investment revaluations and a new path for its oral insulin program.

CV Sciences reported a 12.2% drop in net product sales for 2025 and a 'substantial doubt' about its ability to continue as a going concern, despite improved gross margins and reduced operating losses.

Buda Juice, Inc. reports an 11.8% increase in net sales to $12.6 million for 2025, maintaining profitability despite higher produce costs and IPO-related expenses, as it transitions to a public company.

Wrap Technologies reports increased gross revenue and strategic expansion into new public safety and defense markets, despite continued operating losses in 2025.

Newsmax Inc. reported a 10.7% increase in total revenue to $189.3 million for 2025, driven by broadcasting growth, but saw its net loss widen to $99.5 million amidst significant legal settlements and increased operating costs.

Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported net income for 2025 but faces substantial doubt about its ability to continue as a going concern due to its business combination deadline.

Lightstone Value Plus REIT V, Inc. reported a 4.3% increase in its estimated Net Asset Value per Share to $16.56 as of September 30, 2025, alongside a net income of $5.1 million for the year, driven by asset sales and refinancing activities.

Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1 million for 2025, narrowing from $165.9 million in 2024, as it strategically restructured to prioritize its lead oncology candidate, azenosertib, and extend its cash runway into late 2027.

Cantor Equity Partners IV, a blank check company, reported a net income of $6.13 million for 2025, primarily from Trust Account interest, as it continues its search for a business combination in target sectors like financial services and technology.